23andMe Investor Presentation Deck

Our Scale Enables Real-Time Genetics Health Research¹ (numbers below represent the number of research participants with the condition indicated) 1,876,573 High cholesterol 1,785,456 Depression 1,113,057 Asthma 634,734 Irritable Bowel 534,696 Arrhythmia 9,047 Systemic Sclerosis 358,275 Type 2 Diabetes 2,355,068 APOE e4 carriers (Alzheimer's risk) 667,019 Eczema 107,126 UC / Crohn's 159,135 Coronary Artery 7,334 Sarcoidosis 37,853 Type 1 Diabetes 85,604 Epilepsy 250,764 Psoriasis 64,800 Barrett's Esophagus 42,836 Pulmonary Embolism 4,528 Idiopathic Pulmonary Fibrosis ¹ As of August 2, 2021. 2 As of September 2021. 3 23andMe COVID-19 manuscript live on MedRXiv September 7, 2020. 1,287,060 COVID-19 study participants 2 COVID-19 Research April 6 March 16 June 8 Sept. 7 750K Consumers participated in the COVID-19 study in the first 90 days (2020) Kicked Off Study Launched Study Preliminary Findings Posted Findings³ Re-contactable Customers Participate in Health Research 29

View entire presentation